EUTROPICS PHARMACEUTICALS, INC.

Company Information

Company Name
EUTROPICS PHARMACEUTICALS, INC.
Address
60 GRAMPIAM WAY
DORCHESTER, MA, 02125-
Phone
n/a
URL
n/a
DUNS
604131859
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$726,735.00
3
SBIR Phase II
$2,857,471.00
2
Chart code to be here

Award List

  1. BH3 Profiling as a Companion Diagnostic For Velcade

    Amount: $199,860.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating multiple myeloma. Eutropics is uniquely positioned to improve ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Development of small molecule inhibitor of Mcl-1 for cancer treatment

    Amount: $1,357,725.00

    DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1 (Mcl-1), a member of this protein family, is a key regul ...

    SBIR Phase II 2010 Department of Health and Human Services
  3. Development of small molecule inhibitors of Mcl-1 for cancer treament

    Amount: $326,983.00

    DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1(Mcl-1), a member of this protein family, is a key regu ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA

    Amount: $1,499,746.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unn ...

    SBIR Phase II 2012 Department of Health and Human Services
  5. IGF::OT::IGF OTHER FUNCTIONS RandD- BIOMEDICAL (BASIC RESEARCH)

    Amount: $199,892.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Acute Myelogenous Leukemia (AML) both to improve efficacy and ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government